AU2010343095B2 - Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof - Google Patents

Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof Download PDF

Info

Publication number
AU2010343095B2
AU2010343095B2 AU2010343095A AU2010343095A AU2010343095B2 AU 2010343095 B2 AU2010343095 B2 AU 2010343095B2 AU 2010343095 A AU2010343095 A AU 2010343095A AU 2010343095 A AU2010343095 A AU 2010343095A AU 2010343095 B2 AU2010343095 B2 AU 2010343095B2
Authority
AU
Australia
Prior art keywords
protein
schizochytrium
seq
membrane
microalgal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010343095A
Other languages
English (en)
Other versions
AU2010343095A1 (en
Inventor
Kirk Emil Apt
Anne-Cecile V. Bayne
James Casey Lippmeier
Ross Eric Zirkle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccine Technologies SAS
Original Assignee
Sanofi Vaccine Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Vaccine Technologies SAS filed Critical Sanofi Vaccine Technologies SAS
Publication of AU2010343095A1 publication Critical patent/AU2010343095A1/en
Assigned to SANOFI VACCINE TECHNOLOGIES, S.A.S. reassignment SANOFI VACCINE TECHNOLOGIES, S.A.S. Request for Assignment Assignors: DSM IP ASSETS B.V.
Application granted granted Critical
Publication of AU2010343095B2 publication Critical patent/AU2010343095B2/en
Priority to AU2017202195A priority Critical patent/AU2017202195B2/en
Priority to AU2019206054A priority patent/AU2019206054B2/en
Priority to AU2022203980A priority patent/AU2022203980B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010343095A 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof Active AU2010343095B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017202195A AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2019206054A AU2019206054B2 (en) 2009-12-28 2019-07-17 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2022203980A AU2022203980B2 (en) 2009-12-28 2022-06-08 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29044109P 2009-12-28 2009-12-28
US29046909P 2009-12-28 2009-12-28
US61/290,441 2009-12-28
US61/290,469 2009-12-28
US41335310P 2010-11-12 2010-11-12
US61/413,353 2010-11-12
PCT/US2010/062276 WO2011090731A1 (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017202195A Division AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Publications (2)

Publication Number Publication Date
AU2010343095A1 AU2010343095A1 (en) 2012-08-09
AU2010343095B2 true AU2010343095B2 (en) 2017-01-05

Family

ID=44307127

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2010343095A Active AU2010343095B2 (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2017202195A Active AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2019206054A Active AU2019206054B2 (en) 2009-12-28 2019-07-17 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2022203980A Active AU2022203980B2 (en) 2009-12-28 2022-06-08 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017202195A Active AU2017202195B2 (en) 2009-12-28 2017-04-03 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2019206054A Active AU2019206054B2 (en) 2009-12-28 2019-07-17 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2022203980A Active AU2022203980B2 (en) 2009-12-28 2022-06-08 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Country Status (9)

Country Link
US (3) US20110189228A1 (OSRAM)
EP (3) EP2519635B1 (OSRAM)
JP (5) JP6339548B2 (OSRAM)
CN (2) CN107746869A (OSRAM)
AU (4) AU2010343095B2 (OSRAM)
CA (3) CA3153553A1 (OSRAM)
EA (1) EA022841B1 (OSRAM)
IN (1) IN2012DN06277A (OSRAM)
WO (1) WO2011090731A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI377253B (en) 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
CN104263729B (zh) * 2009-03-16 2020-09-15 帝斯曼知识产权资产有限公司 在网粘菌门微生物中产生蛋白质
WO2011082189A1 (en) * 2009-12-28 2011-07-07 Martek Biosciences Corporation Production of hemagglutinin-neuraminidase protein in microalgae
CA2785653C (en) * 2009-12-28 2018-05-01 Merial Limited Recombinant ndv antigen and uses thereof
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
MX338479B (es) * 2011-03-07 2016-04-19 Dsm Nutritional Products Ag Microorganismos thraustochytrid modificados.
US9404101B2 (en) * 2011-08-24 2016-08-02 Novozymes, Inc. Methods for obtaining positive transformants of a filamentous fungal host cell
EP2877576B1 (en) * 2012-07-24 2019-06-05 BP Corporation North America Inc. Xylose isomerases and their uses
WO2014045191A2 (en) * 2012-09-18 2014-03-27 Myko Tech Private Limited Extracellular polysaccharides from labyrinthulomycetes with broad-spectrum antiviral activities
CA2958463C (en) 2014-10-02 2022-05-03 Evonik Industries Ag Method for raising animals
BR112017006834B1 (pt) * 2014-10-02 2022-04-26 Evonik Operations Gmbh Processo para a preparação de um alimento para animais compreendendo pufas, produto extrudado de alimento para animais e método de criação de animais
CN106793798A (zh) 2014-10-02 2017-05-31 赢创德固赛有限公司 具有高抗磨损性和高水稳定性的含pufa的饲料
CA2958457C (en) 2014-10-02 2022-10-25 Evonik Industries Ag Process for producing a pufa-containing biomass which has high cell stability
AU2016226418B2 (en) 2015-03-02 2022-05-26 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
CA2991707C (en) 2015-07-13 2023-08-01 MARA Renewables Corporation Enhancing microbial metabolism of c5 organic carbon
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
US20190216857A1 (en) * 2016-09-09 2019-07-18 Cornell University Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
CN109996810B (zh) * 2016-11-27 2023-08-22 特里同阿盖亚创新公司 从微藻中纯化重组骨桥蛋白的方法
WO2019173226A1 (en) * 2018-03-05 2019-09-12 Synthetic Genomics, Inc. Organisms and methods for producing glycomolecules with low sulfation
EP3817519A4 (en) 2018-06-27 2022-03-23 Sumitomo Electric Industries, Ltd. ORIGINAL FORM BODY OF FLEXIBLE PRINTED CIRCUIT BOARD, METHOD FOR MANUFACTURING FLEXIBLE PRINTED CIRCUIT BOARD, FOCUSED PHOTOVOLTAIC ENERGY GENERATING MODULE AND ELECTROLUMINESCENT MODULE
US11752175B2 (en) 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
EP4063482A4 (en) * 2019-11-21 2022-12-21 Panasonic Intellectual Property Management Co., Ltd. MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM MANUFACTURING METHOD AND PROTEIN MANUFACTURING METHOD
IT201900024580A1 (it) 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
JP2021186420A (ja) * 2020-06-03 2021-12-13 株式会社三洋物産 遊技機
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
US20240287443A1 (en) * 2021-06-24 2024-08-29 Reliance Industries Limited Recombinant algae and production of spider silk protein from the recombinant algae
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
WO2023081798A1 (en) 2021-11-05 2023-05-11 Sanofi Pasteur Inc. Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
JP2024540290A (ja) 2021-11-05 2024-10-31 サノフイ ヘマグルチニン及びノイラミニダーゼを含むハイブリッド多価インフルエンザワクチン及びそれを使用する方法
CA3239417A1 (en) 2021-11-30 2023-06-08 Yvonne CHAN Human metapneumovirus vaccines
WO2023232976A1 (en) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2023242605A1 (en) 2022-06-14 2023-12-21 Támogatott Kutatócsoportok Irodája Extracellular vesicles for use in therapy
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083869A2 (en) * 2001-04-16 2002-10-24 Martek Biosciences Boulder Corporation Product and process for transformation of thraustochytriales microorganisms
US20060275904A1 (en) * 2005-04-28 2006-12-07 Fuji Photo Film Co., Ltd. Method for introducing a gene into Labyrinthulomycota
US20060286650A1 (en) * 2005-04-28 2006-12-21 Fuji Photo Film Co., Ltd. Vector capable for transformation of labyrinthulomycota
US20080022422A1 (en) * 1999-01-14 2008-01-24 Martek Biosciences Corporation Chimeric pufa polyketide synthase systems and uses thereof
WO2009009876A1 (en) * 2007-07-13 2009-01-22 Medicago Inc. Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5962298A (en) 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
KR20000075076A (ko) * 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU7684201A (en) 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
US20040063188A1 (en) * 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
CA2482244A1 (en) 2002-04-12 2003-10-23 Ilaria Capua Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2005047501A1 (en) * 2003-02-24 2005-05-26 Johns Hopkins University Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
PT1629004E (pt) * 2003-06-05 2008-11-14 Wyeth Corp Composições imunogénicas compreendendo vectores do replicão do vírus da encefalite equina venezuelana e antigénios proteicos de paramixovírus
US7504109B2 (en) * 2004-05-25 2009-03-17 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8936930B2 (en) * 2004-08-05 2015-01-20 Ben-Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CN101605558A (zh) * 2005-08-16 2009-12-16 夏威夷生物技术公司 流感重组亚单位疫苗
CA2642644A1 (en) * 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
AU2007224034B2 (en) * 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
TWI504748B (zh) * 2006-03-15 2015-10-21 Dsm Ip Assets Bv 於異源性生物體中使用多不飽和脂肪酸（ｐｕｆａ）聚酮合成酶系統來製造多不飽和脂肪酸之技術（一）
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
AU2007345682B2 (en) * 2006-07-27 2013-07-18 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
CA2707235C (en) * 2007-11-27 2013-11-19 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 ｎ1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
WO2009117520A2 (en) * 2008-03-19 2009-09-24 Hexion Specialty Chemicals, Inc. Modifier for concrete and cement formulations and methods of preparing the same
CN104263729B (zh) 2009-03-16 2020-09-15 帝斯曼知识产权资产有限公司 在网粘菌门微生物中产生蛋白质
WO2011082189A1 (en) * 2009-12-28 2011-07-07 Martek Biosciences Corporation Production of hemagglutinin-neuraminidase protein in microalgae
CA2785653C (en) * 2009-12-28 2018-05-01 Merial Limited Recombinant ndv antigen and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080022422A1 (en) * 1999-01-14 2008-01-24 Martek Biosciences Corporation Chimeric pufa polyketide synthase systems and uses thereof
WO2002083869A2 (en) * 2001-04-16 2002-10-24 Martek Biosciences Boulder Corporation Product and process for transformation of thraustochytriales microorganisms
US20060275904A1 (en) * 2005-04-28 2006-12-07 Fuji Photo Film Co., Ltd. Method for introducing a gene into Labyrinthulomycota
US20060286650A1 (en) * 2005-04-28 2006-12-21 Fuji Photo Film Co., Ltd. Vector capable for transformation of labyrinthulomycota
WO2009009876A1 (en) * 2007-07-13 2009-01-22 Medicago Inc. Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUHRMANN, M. et al., Methods in Molecular Medicine, 2004, Vol. 94, pages 191-195 *
NWE, N. et al., BMC Microbiology, 2006, Vol. 6, no. 16, pages 1-7 *
SHOJI, Y. et al., 'Plant-expressed HA as a seasonal influenza vaccine candidate', Vaccine, 2008, Vol. 26, No. 23, pages 2930-2934 *
WALKER, T. L. et al., 'Microalgae as bioreactors', Plant Cell Reports, 2005, Vol. 24, No. 11, pages 629-641 *

Also Published As

Publication number Publication date
JP2016047055A (ja) 2016-04-07
EP3505632B1 (en) 2022-08-03
JP7745996B2 (ja) 2025-09-30
EP2519635A4 (en) 2013-06-26
EP4130273A1 (en) 2023-02-08
CA3028175C (en) 2022-05-24
AU2019206054A1 (en) 2019-08-08
AU2022203980B2 (en) 2024-12-12
EP2519635A1 (en) 2012-11-07
JP2018121660A (ja) 2018-08-09
WO2011090731A1 (en) 2011-07-28
AU2010343095A1 (en) 2012-08-09
US20200063174A1 (en) 2020-02-27
JP6666950B2 (ja) 2020-03-18
JP7585382B2 (ja) 2024-11-18
EP2519635B1 (en) 2018-11-21
JP2025114812A (ja) 2025-08-05
EP4130273C0 (en) 2024-06-12
EA201290567A1 (ru) 2013-02-28
IN2012DN06277A (OSRAM) 2015-09-25
US20110189228A1 (en) 2011-08-04
JP6339548B2 (ja) 2018-06-06
US20150110826A1 (en) 2015-04-23
CA3153553A1 (en) 2011-07-28
JP2013515503A (ja) 2013-05-09
JP5838496B2 (ja) 2016-01-06
AU2019206054B2 (en) 2022-03-10
CN102822343B (zh) 2017-10-20
EA022841B1 (ru) 2016-03-31
CA2785971C (en) 2019-02-12
EP4130273B1 (en) 2024-06-12
JP2020096635A (ja) 2020-06-25
AU2017202195A1 (en) 2017-04-20
AU2022203980A1 (en) 2022-06-30
AU2017202195B2 (en) 2019-04-18
CN102822343A (zh) 2012-12-12
JP2023101420A (ja) 2023-07-20
CA3028175A1 (en) 2011-07-28
CN107746869A (zh) 2018-03-02
EP3505632A1 (en) 2019-07-03
CA2785971A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
JP7745996B2 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
JP5838473B2 (ja) 微細藻類におけるヘマグルチニン−ノイラミニダーゼタンパク質の産生方法
US10829794B2 (en) Protein production in microorganisms of the phylum labyrinthulomycota
CN111315408A (zh) 在嗜热毁丝霉(myceliophthora thermophila)中生产流感疫苗
JP5838496B6 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
KR102568329B1 (ko) 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI VACCINE TECHNOLOGIES, S.A.S.

Free format text: FORMER APPLICANT(S): DSM IP ASSETS B.V.

FGA Letters patent sealed or granted (standard patent)